Contineum Therapeutics (CTNM) Interest & Investment Income (2023 - 2026)

Contineum Therapeutics' Interest & Investment Income history runs 4 years deep, the most recent figure standing at $2.3 million for Q2 2026.

• In Q2 2026, Interest & Investment Income rose 15.43% year-over-year to $2.3 million; the TTM figure through Jun 2026 stood at $5.8 million (down 21.64% YoY), while the FY2025 annual figure was $8.2 million, down 7.4% from the prior year.
• Interest & Investment Income for Q2 2026 stood at $2.3 million, up from -$513000.0 in the prior quarter.
• The five-year high for Interest & Investment Income was $2.7 million in Q3 2024, with the low at -$513000.0 in Q1 2026.
• The 4-year median for Interest & Investment Income is $1.8 million (2023), against an average of $1.2 million.
• The sharpest annual moves came in 2025 and 2026: Interest & Investment Income soared 3040.58% in 2025, then tumbled 618.18% in 2026.
• Contineum Therapeutics' Interest & Investment Income stood at $1.8 million in 2023, then jumped by 41.23% to $2.5 million in 2024, then decreased by 20.49% to $2.0 million in 2025, then rose by 16.52% to $2.3 million in 2026.
• Business Quant data shows CTNM's Interest & Investment Income at $2.3 million in Q2 2026, -$513000.0 in Q1 2026, and $2.0 million in Q4 2025.